Spectral AI received FDA clearance to proceed with a commercial rollout, following participation in a Project BioShield contract overseen by the Biomedical Advanced Research and Development Authority.
1 report, 1 independent
Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Spectral AI received FDA clearance to proceed with a commercial rollout, following participation in a Project BioShield contract overseen by the Biomedical Advanced Research and Development Authority.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Biomedical Advanced Research and Development Authority
government organization in Washington D.C., United States
Nothing else this week.
- FDA
Related events
- FDA policy proposal affects the operations of AI, Inc.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.
- The FDA granted 510(k) clearance to SimBioSys's software.
- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.